Emily Walsh Martin, PhD, spoke with Amber Freed, founder and CEO of SLC6A1 Connect, a patient organization focused on accelerating the development of therapies for SLC6A1 patients like her son Maxwell.

CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies with Joseph Glorioso and Rita Perlingeiro
39:58

The Issue – Prepared under pressure: Navigating the due diligence process with Dr. Ralph Brandenberger
39:55

mRNA-based CAR T cell engineering with Norman Drzeniek and Niklas Kotzian
32:35